Thomas Cavanak
16Patents
12h-index
3Co-inventors
71Inventor score
Filing activity: Dec 8, 1981 → Jun 15, 2006
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US4388307A | Galenical compositions | Emerging Cross-Sectional Technologies | 189 | Expired |
| US5639724A | Cyclosporin galenic forms | Human Necessities | 118 | Expired |
| US5759997A | Cyclosporin galenic forms | Human Necessities | 82 | Expired |
| US6306825A | Cyclosporin galenic forms | Human Necessities | 63 | Expired |
| US5652212A | Cyclosporin galenic forms | Human Necessities | 50 | Expired |
| US5977066A | Cyclosporin galenic forms | Human Necessities | 37 | Expired |
| US6468968B2 | Cyclosporin galenic forms | Human Necessities | 34 | Expired |
| US4462983A | Certain ergot peptide alkaloids administered to the nasal mucosa | Physics | 26 | Expired |
| US5759565A | Galenic compositions comprising calcitonin and their use | Human Necessities | 21 | Expired |
| US5753618A | Somatostatin analogue composition and use in treating breast cancer | Emerging Cross-Sectional Technologies | 18 | Expired |
| US5733569A | Galenic compositions comprising calcitonin and their use | Human Necessities | 15 | Expired |
| US4654345A | Occular formulation comprising bromocriptine | Human Necessities | 13 | Expired |
| US6066616A | Somatostatin analogue composition and use in treating breast cancer | Emerging Cross-Sectional Technologies | 12 | Expired |
| US7081445B2 | Cyclosporin galenic forms | Human Necessities | 1 | Expired |
| US4758423A | Certain ergot peptide alkaloids administered to the nasal mucosa | Physics | 1 | Expired |
| US7511014B2 | Cyclosporin galenic forms | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.